Rhumbline Advisers Terns Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 106,451 shares of TERN stock, worth $695,125. This represents 0.0% of its overall portfolio holdings.
Number of Shares
106,451
Previous 96,659
10.13%
Holding current value
$695,125
Previous $266,000
49.25%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding TERN
# of Institutions
136Shares Held
84.3MCall Options Held
185KPut Options Held
89.5K-
Soleus Capital Management, L.P. Greenwich, CT8.17MShares$53.3 Million1.87% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$49.4 Million1.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.5MShares$48.9 Million0.99% of portfolio
-
Morgan Stanley New York, NY7.11MShares$46.4 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$45 Million5.45% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $246M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...